Healthy
Conditions
Brief summary
Investigate the in vivo effects of n-3 PUFA supplementation on inflammation, gene expression and epigenetic signatures. Ex vivo stimulation of peripheral blood mononuclear cells (PBMCs) collected pre and post n-3 supplementation and measurement of it's effect on inflammation, gene expression and epigenetic signatures.
Interventions
DIETARY_SUPPLEMENTOmega-3 Polyunsaturated Fatty Acids Supplementation
28 days of a commercially available supplement. 4 capsules per day.
Sponsors
Bethan Hussey
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy males * Aged between 18 and 30 years
Exclusion criteria
* Females (Due to differences in cell membrane incorporation of n-3 PUFAs between the sexes and the testing schedule being unable to fit in with menstrual cycle, therefore altering the blood markers that are being measured). * Aged below 18 or above 30. * Body mass index (BMI; in kg/ m2), below 18 or above 30. * Use of vitamin or fish oil supplements in the last 6 months. * High habitual oily fish consumption (\<4 servings per month). * Smoking. * Changes in weight in the past 6 months (Dieting) or planning on changing dietary habits. * Habitual use of anti-inflammatory drugs. * Self-reported history of diabetes. * History of heart disease, coagulation/bleeding disorders, metabolic disease or Serious allergy. * Known to have blood-borne virus. * Receipt of inoculations within 2 months of starting the study or the intention to receive such during the study. * Donation of or intention to donate blood within 8 weeks of the first sample or at any point during the intervention.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Epigenetic regulation of Cytokine Genes | Change from Baseline at 7, 14, 21 and 28 days | Blood Sample |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total Cholesterol | Baseline, 7, 14, 21 and 28 days | Biochemical variable |
| LDL (Low density lipoprotein) | Baseline, 7, 14, 21 and 28 days | Biochemical variable |
| HDL (High density lipoprotein) | Baseline, 7, 14, 21 and 28 days | Biochemical variable |
| Triglycerides | Baseline, 7, 14, 21 and 28 days | Biochemical variable |
| Fasting Glucose | Baseline, 7, 14, 21 and 28 days | Biochemical variable |
| Full Blood Count | Baseline, 7, 14, 21 and 28 days | Biochemical variable |
| Height | Baseline, 7, 14, 21 and 28 days | Standard Anthropometric Variables |
| Weight | Baseline, 7, 14, 21 and 28 days | Standard Anthropometric Variables |
| Ethnic background | Baseline, 7, 14, 21 and 28 days | Questionnaire |
| Waist Circumference | Baseline, 7, 14, 21 and 28 days | Standard Anthropometric Variables |
| Systolic and Diastolic Blood Pressure | Baseline, 7, 14, 21 and 28 days | Standard Anthropometric Variables |
| Heart rate | Baseline, 7, 14, 21 and 28 days | Standard Anthropometric Variables |
| Food Diary | Baseline, 7, 14, 21 and 28 days | Self-reporting |
| Exercise Questionnaire | Baseline, 7, 14, 21 and 28 days | Questionnaire |
| Gene expression of Cytokine Genes | Baseline, 7, 14, 21 and 28 days | Extracted PBMCs |
| ex vivo stimulation of Human Derived Blood Cells | Baseline and 28 days | Extracted PBMCs |
| Hip Circumference | Baseline, 7, 14, 21 and 28 days | Standard Anthropometric Variables |
Outcome results
None listed